Palvella Therapeutics (PVLA) Current Assets (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Current Assets data on file, last reported at $263.2 million in Q1 2026.

• Quarterly Current Assets rose 231.36% year-over-year to $263.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263.2 million (up 231.36% YoY) and the FY2025 annual result came in at $59.0 million, down 33.15% from the prior year.
• Current Assets improved to $263.2 million in Q1 2026 per PVLA's latest filing, from $59.0 million in the prior quarter.
• Across five years, Current Assets topped out at $263.2 million in Q1 2026 and bottomed at $7.5 million in Q4 2023.
• The 5-year median for Current Assets is $73.6 million (2022), against an average of $84.2 million.
• The widest annual swing landed in 2023, when Current Assets sank 89.72%; it then soared 1068.97% in 2024.
• Tracing PVLA's Current Assets over 5 years: stood at $73.4 million in 2022, then slumped by 89.72% to $7.5 million in 2023, then soared by 1068.97% to $88.2 million in 2024, then slumped by 33.15% to $59.0 million in 2025, then jumped by 346.25% to $263.2 million in 2026.
• Per Business Quant, the three latest PVLA Current Assets figures stand at $263.2 million (Q1 2026), $59.0 million (Q4 2025), and $66.9 million (Q3 2025).

Peer Comparison